DoseVault
Metabolic Compound

Tirzepatide (Compounded)

Same molecule as Mounjaro/Zepbound, distributed as a compounded multi-dose vial pre-FDA-cutoff.

Scientific Overview

Tirzepatide compounded by 503A pharmacies was widely distributed 2023-Feb 2025. FDA ended discretion Feb 18, 2025; reverted to brand-only thereafter.

Key Research Benefits

  • ✓Weight loss
  • ✓Glucose control
  • ✓Multi-week vial economics

Potential Side Effects

⚠GI side effects
⚠Sulfur burps
⚠Constipation

Research Protocols

Common Dosages

Per-protocol

2.5 → 15 mg
Weekly

“Same titration as Mounjaro”

Note: Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Dose Calculator

🧮 Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

100 Units

or 1.00 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Explore Tirzepatide (Compounded)

Tirzepatide (Compounded) by goal

Read Tirzepatide (Compounded)'s profile filtered through specific research goals.

Tirzepatide (Compounded) for Fat Loss

Molecular Profile

linear
C225H348N48O68
39 AA Sequence

Quick Reference

Status
Research Compound
Category
Metabolic
Common Dosage
2.5 → 15 mg
Weekly

Strictly for research purposes. Not for human consumption.

Related tools

Medical Disclaimer

Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.